When would you fire somebody? But anyways the logic can work both ways. I still think it is more likely than not

$MEIP see ya at $2.00

It's not a leak. It's a guy who is short paying another guy to write his opinion which most points were rebuffed. This is not an incidence of insider information rather an attempt to manipulate the price with an opinion piece attempting to generate fear

Broke major resistance :)

$MEIP building a stairway to heaven :)

$MEIP just wants to bust open :)

The current revenue growth isn't going to impress investors on any exchange. Really need the impressive Q1 numbers to be true. Fingers crossed.

Doesn't hurt that the chart also looks pretty ;)

I am in and ready to rock with the conference next Tuesday. Median overall survival passing 18 months and counting. Best ever recorded for a drug in this cohort. AML data has been more impressive than $CPXX

Jumping in here GLTA

The release makes it sound like they are in financial trouble. I would say there are actually some good things in there but people seem really scared. I am also considering picking some up, when I am not sure though

Glad I got cold feet on this one, see ya later BIND

Exciting times in biotech land

BIND is a riskier bet for April but would run a lot harder on good data, may want to keep an eye on it.

The biggest thing about BIND to me in the iNSITE 1 and iNSITE 2 trials is the potential to show "a safer version of chemotherapy". The drug the company is using, docetaxel, also known as Taxotere, is having issues with causing permanent hair loss because of the potency.

The FDA is very aware of the issue and had a safety label change on it a couple months ago. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm212079.htm

If the company can lessen the severe side effects of chemo via targeting that would be amazing. Fingers crossed.

:) :) :) BIND the next potential winner IMO

Beast mode indeeeed!

$BIND is where it is going to be at next month ;)

What a nice 30% gain to start the day...on to the next one!

Members of GNCA speaking at The 16th annual World Vaccine Congress March 29th-March 31st

Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.
17:40 3/30/2016 "Panel: The future combination cancer immunotherapies with vaccines, checkpoint inhibitors and oncolytic viruses"
11:30 3/31/2016 "Smarter identification of T cell antigens from infectious disease to cancer"

Dr Seth Hetherington, Chief Medical Officer, Genocea Biosciences
17:10 3/30/2016 "Positive top-line Phase II data for genital herpes immunotherapy"

Dr George Siber, CSO of ClearPath Vaccines & Scientific Advisory Board of Genocea, ClearPath Vaccines
9:00 3/30/2016 "Chair’s opening remarks"

Took a position here in anticipation of good GEN-003 data, we will see..

I personally liked the event this morning but it looks like it we will still be stuck longer. I will be back for the Q1 report

An MM I have never seen active before has put up two huge blocks, the first one got bought pretty quickly. To me it looks like one big seller whom I look forward to being gone.

Still drives me mad the company doesn't release news through a better service like business wire or PR newswire

Telkonet would sell well over the current $30M market cap IMO.

I am okay with the profits being eaten up for growth by additions to R&D as well as bolstering the sales force going forward. An increase of over $1,000,000 in Selling, general and administrative as well as an increase of nearly $300,000 for Research and development for the year. 15% improvement in gross margins is also nice. I know people will pick at revenues but I think Jason addressed that issue and we will see top line increases in revenue starting Q1.

Sale not acquisition IMO

Canaccord Genuity Group Inc. is a global, full-service investment banking and financial services company that specializes in wealth management and brokerage in capital markets. It is the largest independent investment dealer in Canada

Landmark transactions have included advising Amaya Gaming Group in its $4.9 billion acquisition of PokerStars and Full Tilt Poker, advising Yamana Gold's $3.9 billion joint acquisition with Agnico Eagle of Osisko Mining, advising Primaris REIT's hostile defence and $5.0 billion sale to H&R REIT and KingSett Capital led consortium, advising Viterra's $6.1 billion sale to Glencore, and advising the $2.2 billion cross-border sale of Daylight Energy to Sinopec, a unit of China Petrochemical Corp. It has also advised on GLENTEL's $670 million sale to Bell Canada in 2014, and the sale of Canada Goose (clothing) to Bain Capital. In 2012, it advised on Extorre Gold Mines' $404 million sale to Yamana Gold.

Telkonet Announces the Engagement of Canaccord Genuity

MILWAUKEE (March 30, 2016) - Telkonet, Inc. (OTCQB: TKOI), creator of the EcoSmart platform of intelligent in-room automation
solutions designed to optimize comfort, energy efficiency and operational analytics in support of the emerging Internet of Things
(IoT), today announced it has retained Canaccord Genuity as its financial advisor to assist management and the Board of Directors in
the evaluation and review of potential strategic and capital raising opportunities aimed at enhancing shareholder value, as well as
to advise the Company with respect to certain transactions that may ultimately be pursued as a result of such review. Jason Tienor,
CEO of Telkonet, stated “We are excited about this new relationship with Canaccord. Canaccord knows our industry, which makes
them a great choice to help the Company evaluate strategic opportunities.”

The Company notes that no decision has been made to pursue any transaction and that there can be no assurance that the review
process will result in the completion of any particular course of action or transaction. The Company has not set a timetable for
completion of the review process, and it does not intend to comment further regarding the review process unless a specific
transaction or other alternative is approved by the Board of Directors, the review process is concluded or it is otherwise determined
that further disclosure is appropriate or required by law.

Also you will notice that insiders bought shares multiple times every month for the entirety of 2015. That abruptly stopped December 23, 2015. If something big was in the works, insiders would be forced to stop making purchases in order to avoid insider trading.

Certainly a correlation in my eyes to the rise in bashing versus the companies potential for a break out, definitely has me thinking about the short interest. I am also curious to hear potential discussion on the R/S and up-list. I would personally welcome the R/S in order to get out of monkey land and potentially reach some institutional investors on the NASDAQ.

I like how he expresses that only bulls have an agenda and bears do not. Between the action of Kross and the addition of Stark I am certainly excited to see how this all shakes out. I do not foresee it being a bad day but we shall see soon :)

I am not sure why I am even responding to someone who doesn't know the difference between there and their. I saw that 8-k and it is by no means a forecast in my opinion. It is a bare minimum requirement for the bank to finance, basically using figures from 2015. This bare minimum is also an annual EBITDA of $521,000, which is not exactly bankrupt by the end of next year. I take that as a worst case scenario and I believe the company has a lot of partnerships that will bear fruit this year that were initiated in the 2nd and 3rd quarter of last year (Trane, Samsung, Kimpton Hotels).

I don't know why you assume the 10k will be a "disaster". It may certainly not exceed expectations or be great, but I highly, highly doubt it will be a disaster. The company will still show a profitable year even while EthoStream is being phased out. It will all be about the material events and whether they are making progress with their partners IMO.

I think if there is no mention of an R/S and up list in the conference call then we are looking at a buyout IMO. Hope you have a great weekend.

I also wish the company wouldn't disseminate news through Accesswire which has horrible exposure. I don't even think iHub or Etrade even picks it up. Not sure why they don't just use Business Wire or PR Newswire like a real company.

I also wish the company wouldn't disseminate news through Accesswire which has horrible exposure. I don't even think iHub or Etrade even picks it up. Not sure why they don't just use Business Wire or PR Newswire like a real company.

Would be nice if the company could give us some contract news like we had with Kimpton Hotels in September of last year. Financials will be a nice lagging update but some real time updates would really be appreciated.

Nice, you can tell the company is trying to get this back over $1.00 organically if they can. May be possible if a big partnering happens in Europe.

Hopefully the bank is simply stating that the company needs to maintain 2015 like numbers for the financing agreement. Not in fact that it is actual revenue forecasts